Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Results from two, multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and cisplatin] and its use is not recommended in that setting.

Here you can find details concerning Tarceva's pivotal Phase III clinical trial for Non-Small Cell Lung Cancer. You can also read about survival and other efficacy results.

Clinical Trial Design

Examine the Tarceva (erlotinib) trials design and study population.

Survival Results

Review the results of trials for Non-Small Cell Lung Cancer and find more information about Tarceva clinical trial efficacy.